This report on global prostate cancer treatment market studies various drugs used for treatment of prostate cancer along with pipeline analysis of upcoming potential drugs. According to National Cancer Institute approximately 12.9% of the men will be diagnosed with prostate cancer at some point during their lifetime. Prostate cancer can be diagnosed before the symptoms start by testing the prostate specific antigen (PSA) in a man’s blood or through the digital rectal exam (DRE). Currently there are a handful of players which are leading the prostate cancer treatment market, but in the future the competition will be more as several blockbuster prostate cancer therapeutic drugs are slated to go off-patent.

For the purpose of this study, the various treatment types studied include biological therapy which includes drugs like Enzalutamid (Xtandi), Abiraterone (Zytiga) and chemotherapy drugs like Docetaxel (Taxotere), Cabazitaxel (Jevtana); Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

The pipeline analysis for prostate cancer treatment market comprises projected market sales of Phase III drugs estimated till 2025. We have estimated sales of very specific molecules based on the type (biological or chemical), sponsor, depicted peak sales by leading market experts and other factors. Few prominent phase III drugs are ProstVac, Tasquinimod Active, ARN-509, ODM-201 and Yervoy etc.

The geographic segmentation of the global prostate cancer treatment market is performed for the regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.